S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
NASDAQ:QLGN

Qualigen Therapeutics Short Interest Ratio and Short Volume

$1.08
-0.07 (-5.65%)
(As of 12/6/2021 12:24 PM ET)
Add
Compare
Today's Range
$1.03
$1.13
50-Day Range
$0.94
$2.56
52-Week Range
$0.93
$4.66
Volume
38,430 shs
Average Volume
20.98 million shs
Market Capitalization
$31.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.67

Qualigen Therapeutics (NASDAQ:QLGN) Short Interest Data

Current Short Volume
1,590,000 shares
Previous Short Volume
1,710,000 shares
Change Vs. Previous Month
-7.02%
Dollar Volume Sold Short
$1.70 million
Short Interest Ratio / Days to Cover
0.3
Last Record Date
November, 15 2021
Outstanding Shares
29,410,000 shares
Float Size
25,800,000 shares
Short Percent of Float
6.16%
Today's Trading Volume
38,430 shares
Average Trading Volume
20,980,204 shares
Today's Volume Vs. Average
-99.82%
Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Qualigen Therapeutics ?

Sign up to receive the latest short interest report for Qualigen Therapeutics and its competitors with MarketBeat's FREE newsletter.

Qualigen Therapeutics (NASDAQ:QLGN) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
11/15/20211,590,000 shares $1.70 million -7.0%6.2%0.3 $1.07
10/29/20211,710,000 shares $1.97 million +4.3%6.7%3.8 $1.15
10/15/20211,640,000 shares $1.92 million -0.6%6.4%3.7 $1.17
9/30/20211,650,000 shares $2.15 million -0.6%6.4%3.5 $1.30
9/15/20211,660,000 shares $2.39 million +16.9%6.5%3.3 $1.44
8/31/20211,420,000 shares $2.23 million -18.9%5.5%2.7 $1.57
8/13/20211,750,000 shares $3.12 million -1.1%6.8%5.2 $1.78
7/30/20211,770,000 shares $3.13 million +2.3%6.9%5 $1.77
7/15/20211,730,000 shares $2.92 million +4.2%6.8%3.4 $1.69
6/30/20211,660,000 shares $3.30 million +9.2%6.5%2.7 $1.99
6/15/20211,520,000 shares $3.19 million -16.0%6.0%2.3 $2.10
5/28/20211,810,000 shares $3.46 million +0.6%7.1%2.5 $1.91
5/14/20211,800,000 shares $2.75 million -6.3%7.1%2.1 $1.53
4/30/20211,920,000 shares $4.22 million +7.9%7.5%1.6 $2.20
4/15/20211,780,000 shares $3.65 million No Change6.3%1.1 $2.05
3/31/20211,780,000 shares $4.63 million -11.4%6.2%1.1 $2.60
3/15/20212,010,000 shares $6.69 million +24.8%7.6%1.2 $3.33
2/26/20211,610,000 shares $5.47 million -10.6%6.1%0.8 $3.40
2/12/20211,800,000 shares $6.98 million -9.6%6.8%1 $3.88
1/29/20211,990,000 shares $7.12 million +3.7%7.5%1.2 $3.58
1/15/20211,920,000 shares $6.62 million No Change7.3%1.5 $3.45













Qualigen Therapeutics (NASDAQ:QLGN) Short Interest Frequently Asked Questions

What is Qualigen Therapeutics' current short interest?

Short interest is the volume of Qualigen Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 1,590,000 shares of QLGN short. 6.16% of Qualigen Therapeutics' shares are currently sold short. Learn More on Qualigen Therapeutics' current short interest.

What is a good short interest percentage for Qualigen Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.16% of Qualigen Therapeutics' floating shares are currently sold short.

Is Qualigen Therapeutics' short interest increasing or decreasing?

Qualigen Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,590,000 shares, a drop of 7.0% from the previous total of 1,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Qualigen Therapeutics' float size?

Qualigen Therapeutics currently has issued a total of 29,410,000 shares. Some of Qualigen Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Qualigen Therapeutics currently has a public float of 25,800,000 shares.

How does Qualigen Therapeutics' short interest compare to its competitors?

6.16% of Qualigen Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Qualigen Therapeutics: NuCana plc (2.65%), Atreca, Inc. (13.48%), Enlivex Therapeutics Ltd. (0.00%), Palatin Technologies, Inc. (2.27%), Puma Biotechnology, Inc. (7.24%), Savara Inc (1.98%), Clever Leaves Holdings Inc. (0.00%), Tyme Technologies, Inc. (2.70%), Concert Pharmaceuticals, Inc. (0.00%), and 180 Life Sciences Corp. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.06 billion), S&P Global Inc. ($8.74 billion), Charter Communications, Inc. ($5.66 billion), Canadian Pacific Railway Limited ($5.43 billion), Wayfair Inc. ($4.23 billion), Palo Alto Networks, Inc. ($3.46 billion), DoorDash, Inc. ($3.41 billion), Teladoc Health, Inc. ($2.84 billion), Etsy, Inc. ($2.76 billion), and Zscaler, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short Qualigen Therapeutics stock?

Short selling QLGN is an investing strategy that aims to generate trading profit from Qualigen Therapeutics as its price is falling. Qualigen Therapeutics' stock is trading down $0.07 today. To short Qualigen Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Qualigen Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Qualigen Therapeutics?

A short squeeze for Qualigen Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of QLGN, which in turn drives the price of the stock up even further.

How often is Qualigen Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including QLGN, twice per month. The most recent reporting period available is November, 15 2021.



This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.